Balasa Dinverno & Foltz LLC lowered its stake in Medical Properties Trust, Inc. (NYSE:MPW) by 4.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,734 shares of the real estate investment trust’s stock after selling 9,077 shares during the period. Medical Properties Trust accounts for 0.4% of Balasa Dinverno & Foltz LLC’s holdings, making the stock its 19th largest holding. Balasa Dinverno & Foltz LLC’s holdings in Medical Properties Trust were worth $3,653,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also added to or reduced their stakes in MPW. Lenox Wealth Advisors LLC bought a new position in shares of Medical Properties Trust during the third quarter valued at $31,000. Cullen Frost Bankers Inc. raised its stake in Medical Properties Trust by 70.9% during the second quarter. Cullen Frost Bankers Inc. now owns 1,832 shares of the real estate investment trust’s stock worth $32,000 after buying an additional 760 shares during the last quarter. Manchester Financial Inc. bought a new position in Medical Properties Trust during the second quarter worth $33,000. Cascade Investment Advisors Inc. bought a new position in Medical Properties Trust during the second quarter worth $35,000. Finally, Private Ocean LLC bought a new position in Medical Properties Trust during the third quarter worth $50,000. 71.94% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Holzgrefe Richard bought 500,000 shares of the company’s stock in a transaction on Friday, November 8th. The shares were purchased at an average cost of $0.09 per share, for a total transaction of $44,500.00. Also, CEO Edward K. Aldag, Jr. sold 101,964 shares of the business’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $19.78, for a total transaction of $2,016,847.92. Following the completion of the transaction, the chief executive officer now owns 2,058,820 shares in the company, valued at $40,723,459.60. The disclosure for this sale can be found here. 1.18% of the stock is currently owned by insiders.
Shares of NYSE MPW traded up $0.04 during mid-day trading on Wednesday, reaching $21.06. 4,947,010 shares of the company’s stock traded hands, compared to its average volume of 4,223,250. Medical Properties Trust, Inc. has a 1-year low of $15.25 and a 1-year high of $21.11. The stock has a market cap of $10.74 billion, a P/E ratio of 15.37, a PEG ratio of 3.74 and a beta of 0.51. The business has a 50-day simple moving average of $20.23 and a 200 day simple moving average of $18.84. The company has a debt-to-equity ratio of 1.02, a current ratio of 6.27 and a quick ratio of 6.27.
Medical Properties Trust (NYSE:MPW) last released its quarterly earnings results on Thursday, October 31st. The real estate investment trust reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.12). Medical Properties Trust had a return on equity of 6.36% and a net margin of 41.57%. The firm had revenue of $224.70 million for the quarter, compared to analysts’ expectations of $221.40 million. During the same quarter last year, the firm posted $0.35 earnings per share. The firm’s revenue for the quarter was up 14.1% compared to the same quarter last year. Equities research analysts anticipate that Medical Properties Trust, Inc. will post 1.33 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, December 12th will be issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 4.94%. The ex-dividend date of this dividend is Wednesday, December 11th. Medical Properties Trust’s dividend payout ratio (DPR) is presently 75.91%.
A number of equities analysts recently weighed in on MPW shares. Zacks Investment Research raised shares of Medical Properties Trust from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Wednesday. Stifel Nicolaus set a $21.00 target price on shares of Medical Properties Trust and gave the stock a “buy” rating in a research note on Monday, August 12th. ValuEngine raised shares of Medical Properties Trust from a “sell” rating to a “hold” rating in a research note on Tuesday. Bank of America assumed coverage on shares of Medical Properties Trust in a research note on Monday, October 14th. They issued a “neutral” rating and a $19.50 price target for the company. Finally, SunTrust Banks lifted their price target on shares of Medical Properties Trust from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $20.27.
About Medical Properties Trust
Medical Properties Trust, Inc is a self-advised real estate investment trust formed to capitalize on the changing trends in healthcare delivery by acquiring and developing net-leased healthcare facilities. MPT's financing model helps facilitate acquisitions and recapitalizations and allows operators of hospitals and other healthcare facilities to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.
Further Reading: Percentage Decliners
Receive News & Ratings for Medical Properties Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Properties Trust and related companies with MarketBeat.com's FREE daily email newsletter.